Connolly et al Management of Aneurysmal Subarachnoid Hemorrhage 1727 Disclosures Writing Group Disclosures Writing Group Member Employment Research Grant Other Research Support Speakers Bureau/ Honoraria Expert Witness Ownership Interest Consultant/ Advisory Board Other E. Sander Connolly, Jr. Columbia University None None None None None None None Alejandro A. Rabinstein Mayo Clinic None None None None None None None J. Ricardo Carhuapoma Johns Hopkins Hospital None None None None None None None Colin P. Derdeyn Washington University School of Medicine (St. Louis) NIH None None Witness for plaintiff* Nfocus* None None Jacques Dion Emory University Hospital None None None None NeuroVasx*; Nfocus Neuromedical*; Sequent Medical* MicroVention/ Terumo* None Randall T. Higashida University of California at San Francisco Medical Center None None None None None None None Brian L. Hoh University of Florida Brain Aneurysm Foundation ; Micrus Endovascular*; NIH ; Thomas H. Maren Foundation None None None None Actelion Pharmaceuticals*; Codman Neurovascular* None Catherine J. Kirkness University of Washington NIH* None None None None None None Andrew M. Naidech Northwestern University/FDA Astellas Pharma*; Gaymar, Inc* None None None None Journal Watch Neurology* None Christopher S. Ogilvy Massachusetts General Hospital Actelion Pharmaceuticals ; NIH None None None None Mizuho America, Inc* None Aman B. Patel Mount Sinai Medical Center None None None None None Cordis/Codman Neurovascular*; Penumbra* None B. Gregory Thompson University of Michigan None None None None None None None Paul Vespa University of California at Los Angeles NIH None None None InTouch Health* EDGE Therapeutics* None This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all writing group members are required to complete and submit. A relationship is considered to be significant if (1) the person receives $10 000 or more during any 12-month period, or 5% or more of the person s gross income; or (2) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. 